-+ 0.00%
-+ 0.00%
-+ 0.00%

Better Buy in the Obesity Drug Race: Novo Nordisk or Eli Lilly?

The Motley Fool·06/26/2026 21:07:53
Listen to the news

Key Points

  • Eli Lilly leads in next‑gen obesity drugs, while Novo Nordisk offers a cheaper, dividend‑paying alternative.

  • Novo’s steady insulin cash flows and new MASH bet could expand growth beyond its core diabetes focus.

Discover how Novo Nordisk (NYSE: NVO) stacks up against Eli Lilly (NYSE: LLY) in the obesity and metabolic race, from GLP‑1 leadership to NASH/MASH optionality and dividend appeal. Watch the video below to see which profile fits your portfolio.

*This video was published on Jun. 26, 2026.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »

Alicia Alfiere, MBA has no position in any of the stocks mentioned. Danny Vena, CPA has no position in any of the stocks mentioned. Karl Thiel has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Eli Lilly and Novo Nordisk. The Motley Fool has a disclosure policy.